Standout Papers
Immediate Impact
6 by Nobel laureates 27 from Science/Nature 80 hit
Citing Papers
Illusory generalizability of clinical prediction models
2024 HitScience
Probiotic-guided CAR-T cells for solid tumor targeting
2023 HitScience
Works of Alan N. Sandler being referenced
IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.
2018
Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC).
2015
Author Peers
Peers are selected by citation overlap in the author's most active subfields. citations · hero ref
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Alan N. Sandler | 3.2k | 2.2k | 1.2k | 869 | 790 | 108 | 5.6k | |
| Marc De Kock | 4.0k 1.2× | 2.0k 0.9× | 949 0.8× | 402 0.5× | 470 0.6× | 146 | 6.2k | |
| Donal J. Buggy | 3.6k 1.1× | 1.6k 0.7× | 1.1k 0.9× | 496 0.6× | 342 0.4× | 185 | 7.4k | |
| Juan P. Cata | 2.0k 0.6× | 990 0.4× | 638 0.5× | 731 0.8× | 303 0.4× | 240 | 6.4k | |
| Alain Borgeat | 4.5k 1.4× | 2.1k 0.9× | 992 0.8× | 228 0.3× | 1.2k 1.5× | 183 | 6.6k | |
| Francis X. McGowan | 1.9k 0.6× | 1.5k 0.7× | 2.0k 1.6× | 1.3k 1.5× | 390 0.5× | 171 | 6.6k | |
| Shung‐Tai Ho | 2.2k 0.7× | 1.2k 0.6× | 444 0.4× | 352 0.4× | 393 0.5× | 183 | 4.0k | |
| Pierre Diemunsch | 2.9k 0.9× | 983 0.4× | 872 0.7× | 521 0.6× | 186 0.2× | 160 | 4.2k | |
| Anthony D. Ivankovich | 3.0k 1.0× | 1.7k 0.8× | 2.0k 1.6× | 1.3k 1.5× | 422 0.5× | 154 | 5.8k | |
| I. Murat | 1.8k 0.6× | 1.9k 0.9× | 1.3k 1.1× | 497 0.6× | 133 0.2× | 137 | 4.2k | |
| Kenneth J. Tuman | 3.1k 1.0× | 1.6k 0.7× | 1.6k 1.3× | 675 0.8× | 500 0.6× | 128 | 4.9k |
All Works
Loading papers...